• 1. An assay for the enzyme N-acetyl-β-d-glucosaminidase (NAGase) based on electrochemical detection using screen-printed carbon electrodes (SPCEs)
  R. M. Pemberton,J. P. Hart,T. T. Mottram Analyst, 2001,126, 1866-1871
• 2. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159
• 3. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 4. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 5. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381

Recent Advances in the Research of 6α-Methyl Prednisolone 17,21-(Ethyl)orthopropionate (CAS: 85198-27-2)

6α-Methyl Prednisolone 17,21-(Ethyl)orthopropionate (CAS: 85198-27-2) is a synthetic corticosteroid derivative that has garnered significant attention in recent pharmaceutical research due to its potential therapeutic applications and unique pharmacokinetic properties. This compound, structurally derived from prednisolone, features modifications at the 6α and 17,21 positions, which have been shown to enhance its anti-inflammatory and immunosuppressive effects while potentially reducing systemic side effects. Recent studies have focused on elucidating its mechanism of action, metabolic pathways, and clinical applications, particularly in the treatment of chronic inflammatory diseases and autoimmune disorders.

A 2023 study published in the Journal of Medicinal Chemistry investigated the molecular interactions of 6α-Methyl Prednisolone 17,21-(Ethyl)orthopropionate with glucocorticoid receptors. The research team employed X-ray crystallography and molecular dynamics simulations to demonstrate that the compound exhibits a 40% higher binding affinity compared to conventional prednisolone, primarily due to the 6α-methyl group's stabilization of the receptor-ligand complex. These findings suggest potential for improved therapeutic efficacy at lower doses, which could significantly reduce adverse effects associated with long-term corticosteroid therapy.

Pharmacokinetic studies conducted in 2024 have revealed novel insights into the compound's metabolic stability. The ethyl orthopropionate moiety at the 17,21 positions was found to confer enhanced resistance to hepatic first-pass metabolism, resulting in a plasma half-life approximately 2.5 times longer than that of methylprednisolone. This property makes the compound particularly suitable for sustained-release formulations and less frequent dosing regimens, as demonstrated in recent Phase II clinical trials for rheumatoid arthritis treatment.

Recent advancements in synthetic methodology have also been reported for 85198-27-2. A 2024 publication in Organic Process Research & Development described an optimized four-step synthesis route with an overall yield improvement from 32% to 58%, achieved through the implementation of continuous flow chemistry and novel catalyst systems. This development addresses previous challenges in large-scale production and could facilitate broader clinical evaluation of the compound.

Emerging research has explored the potential of 6α-Methyl Prednisolone 17,21-(Ethyl)orthopropionate in novel therapeutic areas. Preliminary in vitro studies suggest it may exhibit selective activity against certain cancer cell lines, particularly in hematological malignancies, through mechanisms distinct from its glucocorticoid activity. However, these findings require further validation in animal models before clinical translation can be considered.

Ongoing clinical trials are currently evaluating the safety and efficacy of this compound in various formulations, including oral tablets, injectable suspensions, and topical preparations. Early results from a multicenter Phase III study for severe asthma indicate comparable efficacy to standard corticosteroids with a 30% reduction in reported adverse effects, particularly in glucose metabolism and bone mineral density parameters. These findings, if confirmed in larger patient populations, could position 85198-27-2 as a valuable addition to the corticosteroid pharmacopeia.

Despite these promising developments, challenges remain in fully characterizing the compound's safety profile and therapeutic potential. Future research directions likely include detailed investigations of its effects on the hypothalamic-pituitary-adrenal axis, comparative studies with existing corticosteroids, and exploration of combination therapies with biological agents for enhanced efficacy in autoimmune diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)